Factors influencing dyslipidemia in statin-treated patients in Lebanon and Jordan: results of the Dyslipidemia International Study

References

• World Health Organization Cardiovascular diseases (CVDs) Fact sheet no 3172012 Available from: http://www.who.int/mediacentre/factsheets/fs317/en/index.htmlAccessed February 11, 2014
   Google Scholar
• World Health Organization in collaboration with the World Heart Federation and the World Stroke OrganizationGlobal atlas on cardiovascular disease prevention and control – policies, strategies and interventions2011 Available from: http://www.who.int/cardiovascular_diseases/publications/atlas_cvd/en/Accessed February 11, 2014
   Google Scholar
• World Health OrganizationNCD country profiles – Lebanon2011 Available from: http://www.who.int/nmh/countries/lbn_en.pdfAccessed February 11, 2014
   Google Scholar
• World Health OrganizationNCD country profiles – Jordan2011 Available from: http://www.who.int/nmh/countries/jor_en.pdfAccessed February 11, 2014
   Google Scholar
• GazianoTABittonAAnandSAbrahams-GesselSMurphyAGrowing epidemic of coronary heart disease in low- and middle-income countriesCurr Probl Cardiol20103527211520109979
   PubMed Web of Science ®Google Scholar
• GershBJSliwaKMayosiBMYusufSNovel therapeutic concepts: the epidemic of cardiovascular disease in the developing world: global implicationsEur Heart J201031664264820176800
   PubMed Web of Science ®Google Scholar
• World Health OrganizationGlobal situations and trends: prevalence of tobacco use among adults and adolescents (interactive map)2012 Available from: http://www.who.int/gho/tobacco/use/en/Accessed February 11, 2014
   Google Scholar
• TaylorFWardKMooreTHStatins for the primary prevention of cardiovascular diseaseCochrane Database Syst Rev20111CD00481621249663
   PubMed Web of Science ®Google Scholar
• ZhouQLiaoJKStatins and cardiovascular diseases: from cholesterol lowering to pleiotropyCurr Pharm Des200915546747819199975
   PubMed Web of Science ®Google Scholar
• BaigentCKeechAKearneyPMEfficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statinsLancet200536694931267127816214597
   PubMed Web of Science ®Google Scholar
• DeedwaniaPBarterPCarmenaRReduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets studyLancet2006368953991992816962881
   PubMed Web of Science ®Google Scholar
• KearneyPMBlackwellLCollinsREfficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysisLancet2008371960711712518191683
   PubMed Web of Science ®Google Scholar
• WiltTJBloomfieldHEMacDonaldREffectiveness of statin therapy in adults with coronary heart diseaseArch Intern Med2004164131427143615249352
   PubMedGoogle Scholar
• CzirakyMJWatsonKETalbertRLTargeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care settingJ Manag Care Pharm200814Suppl 8S3S2819891279
   PubMed Web of Science ®Google Scholar
• NestoRWBeyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndromeAm J Cardiovasc Drugs20055637938716259526
   PubMedGoogle Scholar
• GittAKDrexelHFeelyJPersistent lipid abnormalities in statin-treated patients and predictors of LDL-cholesterol goal achievement in clinical practice in Europe and CanadaEur J Prev Cardiol201219222123021450578
   PubMed Web of Science ®Google Scholar
• KotsevaKStagmoMDe BacquerDDe BackerGWoodDTreatment potential for cholesterol management in patients with coronary heart disease in 15 European countries: findings from the EUROASPIRE II surveyAtherosclerosis2008197271071717765905
   PubMed Web of Science ®Google Scholar
• LeiterLALundmanPda SilvaPMDrexelHJungerCGittAKPersistent lipid abnormalities in statin-treated patients with diabetes mellitus in Europe and Canada: results of the Dyslipidaemia International StudyDiabet Med201128111343135121679231
   PubMed Web of Science ®Google Scholar
• SudanoIHessLNollGArnetDPersistent dyslipidemia in statin-treated patients: the focus on comprehensive lipid management survey in Swiss patientsSwiss Med Wkly2011141w1320021574067
   PubMed Web of Science ®Google Scholar
• StrangACKaasjagerHABasartDCStroesESPrevalence of dyslipidaemia in patients treated with lipid-modifying drugs in The Netherlands. Part of the Dyslipidaemia International SurveyNeth J Med201068416817420421658
   PubMed Web of Science ®Google Scholar
• LiberopoulosEVlasserouFMitrogianniZPapageorgantasIElisafMPrevalence and risk distribution of residual dyslipidemia in statin-treated patients in GreeceAngiology201263318419321676964
   PubMed Web of Science ®Google Scholar
• HorganSCrowleyJFeelyJMcAdamBShanahanEVaughanCPrevalence of dyslipidaemia in statin-treated patients in Ireland: Irish results of the DYSlipidaemia International Study (DYSIS)Ir J Med Sci2011180234334921400212
   PubMed Web of Science ®Google Scholar
• GoodmanSGLangerABastienNRPrevalence of dyslipidemia in statin-treated patients in Canada: results of the DYSlipidemia International Study (DYSIS)Can J Cardiol2010269e330e33521076724
   PubMed Web of Science ®Google Scholar
• Gonzalez-JuanateyJRMillanJAlegriaEGuijarroCLozanoJVVitaleGCPrevalence and characteristics of lipid abnormalities in patients treated with statins in primary and secondary prevention in Spain. DYSIS-Spain StudyRev Esp Cardiol2011644286294 Spanish
   PubMed Web of Science ®Google Scholar
• GittAKJungerCSmolkaWBestehornKPrevalence and overlap of different lipid abnormalities in statin-treated patients at high cardiovascular risk in clinical practice in GermanyClin Res Cardiol2010991172373320521058
   PubMed Web of Science ®Google Scholar
• da SilvaPMCardosoSMPersistent lipid abnormalities in patients treated with statins: Portuguese results of the Dyslipidemia International Study (DYSIS)Rev Port Cardiol2011301476321425743
   PubMedGoogle Scholar
• GrundySMCleemanJIMerzCNImplications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelinesCirculation2004110222723915249516
   PubMed Web of Science ®Google Scholar
• RobertsWCThe rule of 5 and the rule of 7 in lipid-lowering by statin drugsAm J Cardiol19978011061079205036
   PubMed Web of Science ®Google Scholar
• CatapanoALReinerZDe BackerGESC/EAS guidelines for the management of dyslipidaemias. The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)Atherosclerosis2011217134621882396
   PubMed Web of Science ®Google Scholar
• EckelRHKahnSEFerranniniEObesity and type 2 diabetes: what can be unified and what needs to be individualized?J Clin Endocrinol Metab20119661654166321602457
   PubMed Web of Science ®Google Scholar
• WilliCBodenmannPGhaliWAFarisPDCornuzJActive smoking and the risk of type 2 diabetes: a systematic review and meta-analysisJAMA2007298222654266418073361
   PubMed Web of Science ®Google Scholar
• DykeJOld habits die hard – smoking ban struggling in LebanonExecutive2013 Available from: http://www.executive-magazine.com/economics-policy/smoking-ban-lebanon-failing/5541Accessed March 5, 2014
   Google Scholar
• BandgarTRFaruquiAAManaging dyslipidaemia: evolving role of combination therapyJ Indian Med Assoc2011109854955222315861
   PubMedGoogle Scholar
• EberBLautschDFauerCCan LDL-cholesterol targets be achieved in a population at high risk? Results of the non-interventional study ACT IICurr Med Res Opin20122891447145422856551
   PubMed Web of Science ®Google Scholar
• ItoMKDyslipidemia: management using optimal lipid-lowering therapyAnn Pharmacother201246101368138123032652
   PubMed Web of Science ®Google Scholar
• TothPPBarterPJRosensonRSHigh-density lipoproteins: a consensus statement from the National Lipid AssociationJ Clin Lipidol20137548452524079290
   PubMed Web of Science ®Google Scholar
• WierzbickiASClarkeREViljoenAMikhailidisDPTriglycerides: a case for treatment?Curr Opin Cardiol201227439840422565137
   PubMed Web of Science ®Google Scholar
• InvestigatorsA-HBodenWEProbstfieldJLNiacin in patients with low HDL cholesterol levels receiving intensive statin therapyN Engl J Med2011365242255226722085343
   PubMed Web of Science ®Google Scholar